Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
